Among women with early‐stage triple‐negative and HER2+ breast cancers, utilization of NACT increased over time, a trend that correlates with previously reported improved rates of pCR and options post‐neoadjuvant treatment with residual disease. Here, ERBB2 is linked to breast cancer.